Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
LEXINGTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting and a presentation by Ali Fattey, CEO, as part of an analyst-moderated fireside chat at the Cowen IO NEXT Summit. The presentations will take place Nov. 10, 2017, at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland.
In an oral presentation at the SITC Meeting, researchers will provide updated preliminary clinical trial data from the Phase 1 dose escalation stage of CA-170, an oral small molecule targeting the immune checkpoints PDL-1 and VISTA. In addition, preclinical data related to combination therapy with CA-327, an oral small molecule PDL-1, VISTA and TIM-3 immune checkpoint antagonist, will be provided in a poster presentation.
Details of these presentations are as follows:
Cowen IO NEXT Summit
| Date/Time: | Friday, Nov. 10, 10:30 a.m. – 10:50 a.m. EST |
| Presenter: | Ali Fattaey, Ph.D., President and Chief Executive Officer |
| Location: | Gaylord National Resort & Convention Center |
Society for Immunotherapy of Cancer 32nd Annual Meeting
CA-170 Oral Presentation:
| Date/Time: | Friday, Nov. 10, 2:30 p.m. – 2:45 p.m. EST |
| Abstract Number: | O32 |
| Presentation Title: | Phase 1 Trial of CA-170, a first-in-class, orally available, small molecule immune checkpoint inhibitor (ICI) dually targeting PD-L1 and VISTA, in patients with advanced solid tumors or lymphomas |
| Location: | Maryland Ballroom, Gaylord National Resort & Convention Center |
CA-327 Poster Presentation:
| Date/Time: | Friday, Nov. 10, 12:30 p.m. – 2:00 p.m., 6:30 p.m. – 8:00 p.m. EST |
| Abstract Number: | P279 |
| Presentation Title: | An oral small molecule combination therapy targeting PD-L1, VISTA and TIM-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer |
| Location: | Prince George Exhibition Hall DE, Gaylord National Resort & Convention Center |
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
For More Information:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6500
jdentzer@curis.com
Media Contact
David Schull
Russo Partners
212-845-4271
david.schull@russopartnersllc.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
